Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 192406, 7 pages
http://dx.doi.org/10.1155/2015/192406
Research Article

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors

1Department of Urology, Yale School of Medicine, New Haven, CT 06520-8058, USA
2Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520-8028, USA
3Department of Pathology, Yale University School of Medicine, New Haven, CT 06520-8023, USA

Received 16 January 2015; Accepted 8 April 2015

Academic Editor: Aurelio Ariza

Copyright © 2015 Brian Shuch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. Harrison, D. J. George, M. S. Walker et al., “‘real world’ treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy,” Clinical Genitourinary Cancer, vol. 11, no. 4, pp. 441–450, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Sunitinib versus interferon alfa in metastatic renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Escudier, T. Eisen, W. M. Stadler et al., “Sorafenib in advanced clear-cell renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 2, pp. 125–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Albiges, S. Oudard, S. Negrier et al., “Complete remission with tyrosine kinase inhibitors in renal cell carcinoma,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 482–487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Johannsen, A. Flörcken, A. Bex et al., “Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis,” European Urology, vol. 55, no. 6, pp. 1430–1439, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Nakaigawa, M. Yao, M. Baba et al., “Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma,” Cancer Research, vol. 66, no. 7, pp. 3699–3705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. L. Nickerson, E. Jaeger, Y. Shi et al., “Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors,” Clinical Cancer Research, vol. 14, no. 15, pp. 4726–4734, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Sato, T. Yoshizato, Y. Shiraishi et al., “Integrated molecular analysis of clear-cell renal cell carcinoma,” Nature Genetics, vol. 45, no. 8, pp. 860–867, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Peruzzi, G. Athauda, and D. P. Bottaro, “The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 39, pp. 14531–14536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Shojaei, J. H. Lee, B. H. Simmons et al., “HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors,” Cancer Research, vol. 70, no. 24, pp. 10090–10100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. T. Gibney, S. A. Aziz, R. L. Camp et al., “C-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma,” Annals of Oncology, vol. 24, no. 2, pp. 343–349, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Miyahara, T. Miyata, K. Shigematsu et al., “Clinical outcome and complications of temporary inferior vena cava filter placement,” Journal of Vascular Surgery, vol. 44, no. 3, pp. 620–624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Betsunoh, S. Mukai, Y. Akiyama et al., “Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma,” Cancer Science, vol. 98, no. 4, pp. 491–498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Cecchi, D. C. Rabe, and D. P. Bottaro, “Targeting the HGF/Met signalling pathway in cancer,” European Journal of Cancer, vol. 46, no. 7, pp. 1260–1270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Schöffski, J. A. Garcia, W. M. Stadler et al., “A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma,” BJU International, vol. 108, no. 5, pp. 679–686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T. K. Choueiri, S. Kumar Pal, D. F. McDermott et al., “A phase I study of cabozantinib (XL184) in patients with renal cell cancer,” Annals of Oncology, 2014. View at Publisher · View at Google Scholar
  17. S. A. Aziz, J. A. Sznol, A. Adeniran et al., “Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors,” BMC Clinical Pathology, vol. 13, article 3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. S. A. Aziz, J. Sznol, A. Adeniran, J. W. Colberg, R. L. Camp, and H. M. Kluger, “Vascularity of primary and metastatic renal cell carcinoma specimens,” Journal of Translational Medicine, vol. 11, no. 1, article 15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. L. Camp, G. G. Chung, and D. L. Rimm, “Automated subcellular localization and quantification of protein expression in tissue microarrays,” Nature Medicine, vol. 8, no. 11, pp. 1323–1327, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. L. B. Jilaveanu, B. Shuch, C. R. Zito et al., “PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metastases,” Journal of Cancer, vol. 5, no. 3, pp. 166–172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Miyata, H. Kanetake, and S. Kanda, “Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma,” Clinical Cancer Research, vol. 12, no. 16, pp. 4876–4881, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Koeppen, C. Lowe, and S. Rost, “Preclinical evaluation of anti-MET antibodies for immunohistochemical staining,” Journal of Clinical Oncology, vol. 32, no. 5, supplement, 2014. View at Google Scholar
  23. B. Cao, Y. Su, M. Oskarsson et al., “Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7443–7448, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. B. S. Knudsen, P. Zhao, J. Resau et al., “A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings,” Applied Immunohistochemistry and Molecular Morphology, vol. 17, no. 1, pp. 57–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Choi, M. K. Kim, J. W. Seo et al., “MET expression in sporadic renal cell carcinomas,” Journal of Korean Medical Science, vol. 21, no. 4, pp. 672–677, 2006. View at Google Scholar
  26. B. Shuch, S. B. Riggs, J. C. LaRochelle et al., “Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm,” BJU International, vol. 102, no. 6, pp. 692–696, 2008. View at Publisher · View at Google Scholar · View at Scopus